Precigen (PGEN) Receivables (2012 - 2026)
Precigen (PGEN) posted quarterly Receivables of $26.7 million for Q1 2026, up 2409.87% year-over-year from $1.1 million in Q1 2025, and up 595.08% quarter-over-quarter from $3.8 million in Q4 2025.
Analysis
Precigen (PGEN) Receivables (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Receivables for 15 consecutive years, with $26.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 2409.87% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $26.7 million (up 2409.87% YoY), while the FY2025 annual figure was $4.4 million, up 793.85% from the prior year.
- Receivables improved to $26.7 million in Q1 2026 per PGEN's latest filing, from $3.8 million in the prior quarter.
- Across five years, Receivables topped out at $26.7 million in Q1 2026 and bottomed at -$11.5 million in Q4 2023.
- Historically, Receivables has averaged $6.4 million across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2023 — Receivables plunged 191.41% — and 2026, when it surged 2409.87%.
- Precigen's Receivables stood at $12.6 million in 2022, then sank by 191.41% to -$11.5 million in 2023, then jumped by 107.98% to $919000.0 in 2024, then surged by 318.06% to $3.8 million in 2025, then surged by 595.08% to $26.7 million in 2026.
- Business Quant data shows PGEN's Receivables at $26.7 million in Q1 2026, $3.8 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 72.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 72.04 Mn |
| Mar 31, 2026 | 26.71 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 919,000.00 |
| Sep 30, 2024 | 729,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 489,000.00 |
| Dec 31, 2023 | -11.52 Mn |
| Sep 30, 2023 | 14.11 Mn |
| Jun 30, 2023 | 14.41 Mn |
| Mar 31, 2023 | 15.52 Mn |
| Dec 31, 2022 | 12.60 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 1.85 Mn |
| Mar 31, 2022 | 24.85 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 21.02 Mn |